CHMP var ikke enig i, at denne mængde medicin er for lille til at være relevant, og kunne endvidere ikke tilslutte sig ansøgerens påstand om, at fase 1 kun vedrører sikkerhed.
The CHMP did not agree that this amount of drug is too small to be relevant and could furthermore not support the Applicant claim that stage 1 is related only to safety.